Does Doxepin Cause QT Prolongation?
Yes, doxepin does cause QT interval prolongation, particularly at therapeutic antidepressant doses (≥75 mg/day), though low-dose formulations (3-6 mg) used for insomnia appear to have minimal to no effect on cardiac repolarization.
Evidence from FDA Drug Labeling
The FDA label for doxepin explicitly documents QT prolongation as a cardiovascular effect 1. The label states that "changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity" and notes that overdose manifestations include cardiac dysrhythmias 1. This is consistent with doxepin's classification as a tricyclic antidepressant (TCA), a drug class known to affect cardiac conduction and repolarization.
Dose-Dependent Effects
The relationship between doxepin dose and QT prolongation is critical:
Antidepressant doses (75-300 mg/day): A controlled study demonstrated that doxepin at a mean daily dose of 169 mg significantly prolonged QTc from 417 msec at baseline to 439 msec at 6 weeks (p<0.03) using signal-averaged ECG 2. This study also showed increased heart rate and a correlation between QRS duration and serum doxepin concentrations (r=0.78, p<0.0001).
Low doses for insomnia (3-6 mg): A thorough QT study evaluated both the therapeutic 6 mg dose and a supratherapeutic 50 mg dose under steady-state conditions 3. Neither dose increased QTc intervals, and the upper bound of 95% confidence intervals remained below the 10 millisecond threshold of concern at all time points. The predicted placebo-corrected change at mean Cmax was -0.88 milliseconds for 6 mg and 2.38 milliseconds for 50 mg.
Clinical Context and Risk Stratification
Guideline perspectives place TCAs, including doxepin, in a category of concern for QT prolongation 4. The European Heart Journal guideline notes that tricyclic antidepressants significantly increased the risk of cardiac arrest (OR 1.69) in a Danish nationwide registry study, though this risk encompasses multiple mechanisms beyond QT prolongation alone.
Key Risk Factors to Assess:
- Baseline cardiac status: Pre-existing heart disease, particularly ischemic heart disease or heart failure
- Congenital long QT syndrome: Genetic predisposition to QT prolongation
- Electrolyte abnormalities: Hypokalemia, hypomagnesemia, hypocalcemia
- Concomitant QT-prolonging medications: The combination substantially increases risk 5
- Age: Elderly patients may be more susceptible
- Hepatic metabolism: Doxepin is metabolized primarily by CYP2D6; inhibitors increase plasma concentrations 1
Practical Clinical Recommendations
For antidepressant dosing (≥75 mg/day):
- Obtain baseline ECG before initiating therapy, particularly in patients with cardiac risk factors
- Monitor ECG at steady state (after dose adjustments) and periodically during maintenance
- Avoid combining with other QT-prolonging agents when possible
- Monitor electrolytes and correct abnormalities promptly
- Consider alternative antidepressants (SSRIs like sertraline, paroxetine, or bupropion) in patients with baseline QTc >450 ms (males) or >470 ms (females), as these agents show no QT prolongation effect 2, 6
For insomnia dosing (3-6 mg):
- Baseline ECG monitoring is generally not required based on thorough QT study data 3
- Standard precautions apply for patients with known cardiac disease or multiple risk factors
Common Pitfalls
- Assuming all TCAs have identical cardiac effects: While doxepin prolongs QT, the magnitude varies with dose and individual patient factors
- Overlooking drug interactions: CYP2D6 inhibitors (quinidine, SSRIs, antiarrhythmics) can dramatically increase doxepin levels and cardiac effects 1
- Relying on standard 12-lead ECG alone: Signal-averaged ECG may detect subtle changes not visible on standard ECG 2
- Ignoring the distinction between insomnia and antidepressant formulations: The 3-6 mg insomnia doses have fundamentally different cardiac safety profiles than antidepressant doses
The bottom line: Doxepin's QT-prolonging effect is dose-dependent and clinically significant at antidepressant doses, requiring ECG monitoring in at-risk patients, while low-dose formulations for insomnia appear safe from a cardiac repolarization standpoint.